Clinical Trial Update: Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the combination of tremelimumab and durvalumab with concomitant radiotherapy in advanced non-small cell lung cancer patie…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Sheba Medical Center | Conditions: Metastatic or Locally Advanced NSCLC | Phase 2 | Status: ACTIVE_NOT_RECRUITING